Arcus CEO Sells Shares Via Trust

Arcus Biosciences, Inc. President Juan C. Jaen reported the sale of 68,569 shares on July 9 and July 10, 2026. These transactions were conducted indirectly through a trust, a method often employed for estate planning or portfolio management. This indirect sale structure allowed Jaen to manage his holdings while maintaining a separate direct equity stake in the company.

Despite this disposition, Jaen remains a significant stakeholder in Arcus Biosciences. His total beneficial ownership amounts to approximately 1.2 million shares across both direct and indirect accounts, as detailed in the SEC Form 4 filing. His reported holdings also encompass unvested restricted stock units and derivative securities.

Arcus Biosciences is a clinical-stage biopharmaceutical company dedicated to developing cancer therapies. As of July 10, 2026, the company's market capitalization was approximately $3 billion. Its financial performance in the trailing twelve months showed revenue of $236 million against a net loss of $350 million.

The timing of these sales was governed by a Rule 10b5-1 trading plan. This means the transactions were non-discretionary at the time of execution, having been adopted in advance to allow insiders to diversify portfolios or manage liquidity without relying on non-public information.